0000000000703969

AUTHOR

Ramin Tadayoni

showing 2 related works from this author

Development and validation of a risk-prediction nomogram for poor functional response one year after treatment with anti-VEGF in naive-diabetic macul…

2018

International audience

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organs[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansComputingMilieux_MISCELLANEOUS[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Ranibizumab in patients with neovascular age-related macular degeneration in real-world clinical settings in France: 1-year data from the LUMINOUS (T…

2016

Purpose : LUMINOUS™ (NCT01318941; initiated March 2011) is the largest, prospective, observational, global study in the field of medical retina. LUMINOUS™ is an ongoing 5-year study that is designed to evaluate the long-term safety, effectiveness, treatment patterns, and health-related quality of life associated with ranibizumab (RBZ) 0.5 mg treatment across all approved indications in 30,000 patients from routine clinical practice. We present the 1-year data from the French patients included in LUMINOUS™. Methods : Overall, 17, 545 adult patients with neovascular age-related macular degeneration (nAMD) were enrolled before March 2014; of these 9125 adult nAMD patients with a potential for …

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyOrganes des sens[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyOphtalmologySensory Organsdmladonnées de la rechercheMédecine humaine et pathologieHuman health and pathologydégénérescence maculaireFranceComputingMilieux_MISCELLANEOUS[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct